ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1874

Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis

Kaitlin Quinn1, Hugh Alessi2, Emily Rose3, Mark A. Ahlman4, Christopher Redmond4, Yiming Luo4, Ertugrul Cagri bolek5, Carol Langford6, Cristina Ponte7, Peter Merkel8 and Peter Grayson9, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Washington, DC, 2National Institutes of Health, Bethesda, Maryland, 3Case Western, Cleveland Heights, OH, 4National Institutes of Health, Bethesda, MD, 5Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, 6Cleveland Clinic, Moreland Hills, OH, 7Hospital de Santa Maria, Lisbon, Portugal, 8University of Pennsylvania, Philadelphia, PA, 9National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD

Meeting: ACR Convergence 2021

Keywords: clinical trial, Disease Activity, FDG-PET, Takayasu.s arteritis, Vasculitis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Tuesday, November 9, 2021

Title: Vasculitis – Non-ANCA-Associated & Related Disorders Poster II (1862–1888)

Session Type: Poster Session D

Session Time: 8:30AM-10:30AM

Background/Purpose: Disease activity assessment can be challenging in Takayasu’s arteritis (TAK), which can lead to difficulty in determining eligibility for enrollment into randomized clinical trials (RCTs). FDG-PET can complement clinical assessment of disease activity. The study objective was to determine whether incorporation of PET data, in addition to clinical assessment, influences decisions about trial enrollment in TAK.

Methods: An online survey was completed by physicians with expertise in TAK. Participants were asked background questions, including personal experience with use of PET. Clinical vignettes of commonly-encountered clinical scenarios were presented, based on actual cases derived from a prospective, observational cohort. In part A of each vignette, clinical symptoms, examination findings, acute phase reactant (APR) levels, and angiographic data were presented. Participants were asked if there was sufficient evidence of active vasculitis to enroll into a RCT studying a new treatment agent and to rate level of confidence about their assessment (scale of 0-100). In part B, detailed information from the same patient’s PET scan was presented and participants were again asked whether they would enroll the patient into a RCT and level of confidence about their assessment. Generalized linear mixed models, adjusting for correlated data, were used to evaluate associations between PET activity, APR levels, and enrollment decisions.

Results: Sixty-eight vasculitis experts completed the survey. The majority of physicians were from Europe [n=45 (66%)] or North America [n=16 (24%)] and most were rheumatologists [n=54 (79%)]. Physicians had varying experience with managing patients with TAK: < 10 patients [n=15 (22%)], 10-40 patients [n=32 (47%)], and >40 patients [n=21 (31%)]. Most physicians reported using PET to diagnose TAK [n=56 (82%)] and to monitor disease activity [n=45 (66%)].

In part A of the vignettes, greater variability in trial enrollment decision was observed in cases of constitutional symptoms alone (e.g. fatigue) and elevated APR levels (Cases 4-6) (TABLE 1).

In Part B, level of confidence improved when PET findings aligned with clinical assessment from Part A (Case 1,3,8). In cases where PET findings did not align with clinical assessment in part A (e.g. absent clinical symptoms with active PET scan, “subclinical inflammation”), the degree of variability about whether to enroll/not enroll increased in Part B and level of confidence worsened (Case 2, 7). In cases with the highest variability about enrollment in part A (Cases 4-6), PET activity drove the decision of whether to enroll in Part B and level of confidence improved. PET activity and APR levels independently contributed to trial enrollment decisions (TABLE 2).

Conclusion: Physicians vary about which patients with TAK should be enrolled into RCTs. Incorporation of PET findings with clinical assessment influences trial enrollment decisions and improves physician confidence about disease activity assessment. Cases of subclinical inflammation pose unique challenges for trial enrollment. Future RCTs in TAK should consider incorporating PET findings into eligibility criteria.


Disclosures: K. Quinn, None; H. Alessi, None; E. Rose, None; M. Ahlman, None; C. Redmond, None; Y. Luo, None; E. bolek, None; C. Langford, None; C. Ponte, None; P. Merkel, AbbVie, 2, 5, AstraZeneca, 2, 5, Boeringher-Ingelheim, 2, 5, Bristol-Myers Squibb, 2, 5, ChemoCentryx, 2, 5, CSL Behring, 2, Dynacure, 2, Eicos, 2, EMDSerono, 2, Forbius, 2, 5, Genentech/Roche, 2, 5, Genzyme/Sanofi, 2, 5, GlaxoSmithKline, 2, 5, InflaRx, 2, 5, Jannsen, 2, Kiniksa, 2, Magenta, 2, Neutrolis, 2, Novartis, 2, Pfizer, 2, Sanofi, 5, Star Therapeutics, 2, Takeda, 2, Talaris, 2, UpToDate, 9; P. Grayson, None.

To cite this abstract in AMA style:

Quinn K, Alessi H, Rose E, Ahlman M, Redmond C, Luo Y, bolek E, Langford C, Ponte C, Merkel P, Grayson P. Using 18F-fluorodeoxyglucose Positron Emission Tomography to Standardize Clinical Trial Recruitment in Takayasu’s Arteritis [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/using-18f-fluorodeoxyglucose-positron-emission-tomography-to-standardize-clinical-trial-recruitment-in-takayasus-arteritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/using-18f-fluorodeoxyglucose-positron-emission-tomography-to-standardize-clinical-trial-recruitment-in-takayasus-arteritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology